Regeneron Pharmaceuticals (REGN) Competitors

Amgen (NASDAQ:AMGN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, community ranking, earnings, analyst recommendations and dividends.

Is AMGN or REGN more profitable?

Regeneron Pharmaceuticals has a net margin of 31.07% compared to Amgen's net margin of 12.24%. Amgen's return on equity of 176.32% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	12.24%	176.32%	11.71%
Regeneron Pharmaceuticals	31.07%	16.32%	12.76%

Do analysts recommend AMGN or REGN?

Amgen currently has a consensus price target of $314.09, suggesting a potential upside of 3.66%. Regeneron Pharmaceuticals has a consensus price target of $973.13, suggesting a potential upside of 38.95%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	10 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.46
Regeneron Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.76

Do institutionals and insiders hold more shares of AMGN or REGN?

76.5% of Amgen shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 0.7% of Amgen shares are owned by insiders. Comparatively, 7.5% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has better valuation & earnings, AMGN or REGN?

Regeneron Pharmaceuticals has lower revenue, but higher earnings than Amgen. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$33.42B	4.87	$4.09B	$7.55	40.13
Regeneron Pharmaceuticals	$14.20B	5.39	$4.41B	$38.28	18.29

Does the MarketBeat Community prefer AMGN or REGN?

Amgen received 2 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 72.03% of users gave Amgen an outperform vote while only 66.93% of users gave Regeneron Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Amgen	Outperform Votes 1550 72.03%	Underperform Votes 602 27.97%
Regeneron Pharmaceuticals	Outperform Votes 1548 66.93%	Underperform Votes 765 33.07%

Which has more risk & volatility, AMGN or REGN?

Amgen has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500.

Does the media refer more to AMGN or REGN?

In the previous week, Amgen had 5 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 58 mentions for Amgen and 53 mentions for Regeneron Pharmaceuticals. Amgen's average media sentiment score of 1.57 beat Regeneron Pharmaceuticals' score of 0.46 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	52 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Regeneron Pharmaceuticals	28 Very Positive mention(s)	2 Positive mention(s)	22 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Regeneron Pharmaceuticals beats Amgen on 11 of the 19 factors compared between the two stocks.